UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 6, 2006
Pharma-Bio Serv, Inc.
(Exact name of registrant as specified in its charter)
Delaware 000-50956 20-0653570
- --------------------------------------------------------------------------------
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation) Identification No.)
373 Mendez Vigo, Suite 110, Dorado, Puerto Rico 00646
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (787) 278-2709
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Item 4.01 Changes in Registrant's Certifying Accountant.
On March 6, 2006, our audit committee dismissed Raich Ende Malter & Co.
LLP ("Raich Ende") as our independent public accountant and selected Kevane Soto
Pasarell Grant Thornton LLP ("Kevane") to serve as our independent public
accountant for the year ending October 31, 2006. At no time since its engagement
has Kevane had any direct or indirect financial interest in or any connection
with us or any of our subsidiaries other than as independent accountant.
Our financial statements at June 30, 2005 and for the year then ended
and at June 30, 2004 and the period from January 14, 2004 (inception) to June
30, 2004 were audited by Raich Ende. The audit report of Raich Ende did not
contain an adverse opinion or disclaimer of opinion and was not modified as to
uncertainty, audit scope or accounting principles. There were no disagreements
with Raich Ende during the period ended June 30, 2005 or during the period
subsequent to June 30, 2005 on any matter of accounting principles or practices,
financial statement disclosure or auditing scope or procedure.
Kevane served as the independent accountant for our subsidiary, Plaza
Consulting Group, Inc. ("Plaza"), for October 31, 2005 and the two years in the
period then ending. Plaza consulted Kevane in connection with the Form 8-K,
including the pro forma financial statements included therein, relating to the
reverse acquisition.
Item 9.01 Financial Statements and Exhibits.
Exhibits
16.1 Letter from Raich Ende Malter & Co. LLP
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PHARMA-BIO SERV, INC.
(Registrant)
Date: March 24, 2006 /s/ Elizabeth Plaza
----------------------------------------
Elizabeth Plaza, Chief Executive Officer